FINWIRES · TerminalLIVE
FINWIRES

$CDNA

8 stories mentioning CDNAUpdated just now

Every FINWIRES story that references CDNA, newest first.

Sectors

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks fell late Friday afternoon with the NYSE Healthcare Index shedding 0.7% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.4%.The iShares Biotechnology ETF (IBB) dropped 1.7%.In corporate news, Novo Nordisk (NVO) shares fell past 9% after it said a late-stage trial of ziltivekimab was unable to reduce major adverse cardiovascular events, compared with a placebo.AbbVie (ABBV) lowered its full-year earnings guidance on Friday to account for the expected dilution from its planned acquisition of Apogee Therapeutics (APGE), despite reporting stronger-than-expected Q2 results. AbbVie shares were down 2%.CareDx (CDNA) shares jumped past 14% a day after Q2 results beat market expectations and the company lifted its 2026 revenue guidance.Replimune (REPL) shares surged 101% after the company late Thursday reported a favorable outcome of the US Food and Drug Administration's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in advanced melanoma.

$ABBV$CDNA$NVO$REPL
Sectors

Sector Update: Healthcare

Healthcare stocks fell late Friday afternoon with the NYSE Healthcare Index shedding 0.7% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.4%.The iShares Biotechnology ETF (IBB) dropped 1.7%.In corporate news, CareDx (CDNA) shares rose 15% a day after Q2 results beat market expectations and the company lifted its 2026 revenue guidance.

$CDNA
Wire

Top Midday Gainers

Replimune (REPL) stock soared 94% after the company late Thursday reported a favorable outcome of the US Food and Drug Administration's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in advanced melanoma.The committee voted 10 to 3 that the efficacy results from the IGNYTE study are evaluable and clinically meaningful, it said.After the outcome, Cantor Fitzgerald upgraded Replimune to overweight from neutral.More than 23.4 million shares traded intraday, compared with a daily average of about 5.85 million.CareDx (CDNA) reported Q2 non-GAAP earnings and revenue late Thursday that beat market expectations. The company also lifted its 2026 revenue guidance.Shares jumped 13%, with intraday trading volume rising to more than 1.3 million from a daily average of about 905,000.Amazon's (AMZN) web services cloud-computing unit reported overnight the fastest sales growth in 18 quarters, helping the e-commerce giant handily exceed market expectations for Q2 earnings and revenue.Shares advanced 15% amid a rise in intraday trading volume to over 84.7 million from a daily average of roughly 48.2 million.Price: $10.62, Change: $+5.21, Percent Change: +96.30%

$AMZN$CDNA$REPL
Insider Trading

Caredx Insider Sold Shares Worth $1,040,243, According to a Recent SEC Filing

Hannah Valantine, Director, on July 16, 2026, sold 28,779 shares in Caredx (CDNA) for $1,040,243. Following the Form 4 filing with the SEC, Valantine has control over a total of 36,686 common shares of the company, with 36,686 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1217234/000185560826000004/xslF345X05/form4-07172026_080746.xml

$CDNA
Insider Trading

Caredx Insider Sold Shares Worth $4,458,637, According to a Recent SEC Filing

John Walter Hanna Jr, Director, President, and CEO, on July 16, 2026, sold 118,000 shares in Caredx (CDNA) for $4,458,637. Following the Form 4 filing with the SEC, Hanna has control over a total of 653,448 common shares of the company, with 653,448 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1217234/000178112726000012/xslF345X05/form4-07172026_080725.xml

$CDNA
Wire

CareDx Shares Rise After Surveillance Testing Coverage Affirmed

CareDx (CDNA) shares were up over 30% in Thursday trading after the company said a final policy affirmed coverage across its transplant surveillance offerings in kidney, heart, and lung.The firm reported earlier the finalization of the Medicare Local Coverage Determination process related to molecular testing for solid organ allograft rejection.The final Local Coverage Determination is expected to take effect on Aug. 30, CareDx added.Price: $39.01, Change: $+9.26, Percent Change: +31.11%

$CDNA
Insider Trading

Caredx Insider Sold Shares Worth $279,728, According to a Recent SEC Filing

Hannah Valantine, Director, on June 12, 2026, sold 12,103 shares in Caredx (CDNA) for $279,728. Following the Form 4 filing with the SEC, Valantine has control over a total of 36,686 common shares of the company, with 36,686 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1217234/000185560826000003/xslF345X05/form4-06162026_090624.xml

$CDNA
Insider Trading

Caredx Insider Sold Shares Worth $528,443, According to a Recent SEC Filing

John Walter Hanna Jr, Director, President and CEO, on June 11, 2026, sold 21,998 shares in Caredx (CDNA) for $528,443. Following the Form 4 filing with the SEC, Hanna has control over a total of 649,642 common shares of the company, with 649,642 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1217234/000178112726000008/xslF345X05/form4-06152026_090627.xml

$CDNA

Track with the FINWIRES app suite

FolioX
FolioX
Track CDNA in your portfolio
WheelAI
WheelAI
Analyze CDNA options with the wheel strategy
StockInsider
StockInsider
See market sentiment on CDNA